Global biopharma company Mallinckrodt has entered into an agreement to sell its wholly owned subsidiary BioVectra to an affiliate of H.I.G. Capital, a global private equity investment firm, for approximately $250 million.   BioVectra is a contract development and manufacturing organization (CDMO) whose global client base includes many of the top biopharmaceutical companies in the world. The company has a mix of capabilities, with core growth engines in complex chemistry, biologics and drug devel...